Valuation: Gilead Sciences, Inc.

Market Cap 186B 162B 153B 139B 261B 17,832B 261B 1,831B 706B 9,083B 699B 684B 29,312B P/E 2026 *
-45.4x
P/E 2027 * 18.7x
Enterprise Value 203B 177B 167B 152B 284B 19,436B 285B 1,995B 769B 9,901B 762B 745B 31,949B EV / Sales 2026 *
6.61x
EV / Sales 2027 * 5.97x
Free-Float
99.88%
Yield 2026 *
2.19%
Yield 2027 * 2.23%
18/09 Dr. Reddy's Confirms License for Gilead's Yearly-Once HIV Drug; Shares Up 2% MT
17/09 Gilead Sciences Insider Sold Shares Worth $432,646, According to a Recent SEC Filing MT
17/09 Gilead Sciences, Inc. Expands Royalty-Free Voluntary Licensing Agreements For Lenacapavir With Dr. Reddy?s Laboratories Limited, Emcure Pharmaceuticals Limited, Eva Pharma For Pharmaceutical Industries S.A.E., Ferozsons Laboratories Limited, Hetero And Mylan Laboratories Limited CI
16/09 Gilead Sciences Expands Licensing Agreements for HIV Treatment MT
16/09 Gilead Sciences, Inc. and Pan American Health Organization Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean CI
16/09 Gilead Sciences, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 10:45 AM
16/09 Gilead Sciences Expands Lenacapavir Access to 14 Countries MT
16/09 Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean RE
11/09 Gilead Sciences, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 10:55 AM
10/09 HSBC Adjusts Price Target on Gilead Sciences to $175 From $155, Keeps Buy Rating MT
10/09 Gilead Sciences, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 11:00 AM
09/09 Assembly Biosciences Exercises Option to Share US Costs, Profits for Herpes Program With Gilead MT
09/09 Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program With Gilead DJ
1 week+2.05%
Current month+4.55%
1 month+4.64%
3 months+20.50%
6 months+8.61%
Current year+24.35%
1 week 125.72
Extreme 125.72
131.66
1 month 124.2
Extreme 124.2
131.66
3 years 58.35
Extreme 58.35
131.66
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
+2.36%-0.29%+37.33%+86.86% 186B
+1.04%+2.34%+54.30%+111.75% 1,028B
-0.19%+1.18%+54.68%+66.69% 651B
+0.20%+1.04%+18.82%+72.38% 466B
+2.24%+5.98%+37.61%+42.44% 346B
+0.90%+3.66%+18.79%+25.03% 266B
+0.48%+7.28%+11.11%+14.70% 259B
+1.95%+3.06%+37.47%+45.93% 208B
-7.65%-5.95%-33.09%-60.76% 191B
+0.30%+2.83%+33.84%+100.03% 186B
Average +0.04%+3.26%+27.09%+50.51% 400.19B
Weighted average by Cap. +0.46%+3.09%+35.85%+65.98%

Financials

2026 *2027 *
Net sales 30.7B 26.77B 25.21B 22.96B 43.05B 2,941B 43.1B 302B 116B 1,498B 115B 113B 4,835B 32.68B 28.5B 26.84B 24.44B 45.83B 3,131B 45.88B 321B 124B 1,595B 123B 120B 5,147B
Net income -4.27B -3.73B -3.51B -3.2B -5.99B -410B -6B -42.04B -16.2B -209B -16.06B -15.7B -673B 10.28B 8.96B 8.44B 7.68B 14.41B 984B 14.43B 101B 38.95B 501B 38.6B 37.74B 1,618B
Net Debt 16.75B 14.6B 13.75B 12.52B 23.48B 1,604B 23.51B 165B 63.47B 817B 62.9B 61.51B 2,637B 9.12B 7.96B 7.49B 6.82B 12.79B 874B 12.81B 89.74B 34.59B 445B 34.27B 33.52B 1,437B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
-
Date Price Change
22/09/26 EUR 131.66 +2.36%
18/09/26 EUR 128.63 0.00%
17/09/26 EUR 128.63 +2.20%
16/09/26 EUR 125.86 0.00%
15/09/26 EUR 125.86 -2.44%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
150.11USD
Average target price
158.15USD
Spread / Average Target
+5.35%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!